Single-center Haemodialysis Experience in India During COVID-19.

Introduction: Since COVID-19 has been announced as a pandemic, outcome of dialysis patients in terms of morbidity and mortality from India is lacking. We studied the clinical, epidemiological features of COVID-19 along with outcome in terms of mortality in our dialysis cohort. Methods: Data of End-Stage Kidney Disease (ESKD) patients who were admitted in COVID-19 designated hospital block as positive and suspected patients from 1st April 2020 to 31st July 2020 was retrieved. Data about epidemiological characteristics, clinical features, mortality outcomes of COVID-19 positive and negative patients were analyzed. Results: A total of 97 ESKD patients were admitted during the study period, of which 44 (45.4%) and 53 (54.6%) patients were found to be COVID-19 positive and negative respectively. The mean age of COVID positive patients was 46 years with 54.5% being female. Only three patients (6.8%) remained asymptomatic throughout the course of illness. Amongst COVID-19 positive, 20 (45.45%) were severely ill while 18 (40.9%) were having mild illnesses. Breathlessness (65.9%) and fever (61.4%) were common symptoms. The death occurred in 17 (38.6%) and 25 (47.1%) COVID-19 positive and negative ESKD patients respectively. 14 (82.3%) patients who expired amongst COVID-19 positive were having severe illness and significantly more were associated with negligible residual renal function. Conclusions: Breathlessness and fever were common symptoms amongst COVID-19 ESKD patients. Very few patients remained asymptomatic in our cohort and significantly more mortality is observed in severely ill patients and those with negligible residual renal function.

Minimal Change Disease After Second Dose of Covishield Vaccination

Minimal change disease has been associated with different types of vaccinations, and several case reports have associated the development of this disease with COVID vaccinations as well. We present here a case report of a 19-year-old male who developed minimal change nephrotic syndrome following the second dose of Covishield ChAdOx1 nCoV vaccine. He had received his first dose 2 months prior which was uneventful. He developed fever 3 days after second vaccination and 1 week later developed edema, frothuria, and oliguria. His reports showed a 24-h urine protein of 3.7 g per day, serum creatinine of 1.9 mg/dL, and serum albumin of 1.9 g/dL. He underwent a kidney biopsy which showed features consistent with minimal change disease. He was started on prednisolone at 1 mg/kg body weight. He responded well to treatment and attained complete remission after 33 days of steroids with 24-h urine protein of 195 mg/day, serum creatinine of 0.6 mg/dL, and serum albumin of 5.1 g/dL. This case highlights the possibility of occurrence of minimal change disease post Covishield vaccination even after the second dose despite an uneventful first dose.